NCT00537355 - An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber | Biotech Hunter

Enrollment

271

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

May 31, 2008

Conditions

Rhinitis, Allergic, Seasonal

Interventions

BIOLOGICAL

Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate

6 weekly subcutaneous injections (escalating doses of 3 mcg to 30 mcg)

DRUG

Histamine

6 weekly subcutaneous injections (escalating doses of 0.22 mcg to 1.1 mcg)

Trial Locations (6)

Allied Research International Inc., Mississauga

Alpha Medical Research Inc., Mississauga

Allergy & Asthma Research Centre, Ottawa

Division of Clinical Immunology and Allergy, The McGill University Health Centre, Montreal

Anapharm, Montreal

Centre De Recherche Appliquée en Allergie De Québec, Québec